Cardiovascular Disease: Risk Factors Related to Thrombosis
The risk of coronary heart disease (CHD) is consistently higher among men than women. Mortality rates among premenopausal women in developed countries are about 20–30% lower than rates among men of similar age. Hormonal factors play a critical role in protecting women from the risk associated with other genetic and/or environmental factors. Gender differences in mortality, indeed, diminish following natural or surgical menopause. Among others, the systems of coagulation and fibrinolysis are related to CHD development. Increased levels of fibrinogen and coagulation factor VII (F VII) have been all consistently and independently related to the risk of myocardial infarction (MI). Moreover, the plasma levels of these proteins can be modulated by sex hormones. In particular the levels of F VII are lower in premenopausal women than in males. They increase after menopause or under contraceptives, while conflicting effects have been reported after hormone replacement therapy (HRT).
KeywordsEndometrial Cancer Hormone Replacement Therapy Medroxyprogesterone Acetate Cyproterone Acetate Estradiol Valerate
Unable to display preview. Download preview PDF.
- 5.Eaker ED, Castelli W. Coronary heart disease and its risk factors among women in the Framingham Study. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, editors. Coronary heart disease in women. Bethesda, Maryland: National Heart, Lung and Blood Institute, National Institutes of Health, 1987.Google Scholar
- 11.Meade TW, Imeson JD, Haines AP, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet 1986;1:22–4.Google Scholar
- 16.Di Castelnuovo A, D’Orazio A, Amore C, et al. Genetic modulation of coagulation factor VII plasma levels: contribution of different polymorphisms and gender-related effects. Thromb Haemost 1998; in press.Google Scholar
- 20.The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233–41.CrossRefGoogle Scholar
- 24.Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard A, Schnohr P, Nordestgaard BG. A common mutation in the b-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997;99:3034–39.PubMedCrossRefGoogle Scholar
- 25.Zito F, Di Castelnuovo A, Amore C, D’Orazio A, Donati MB, Iacoviello L. BclI polymorphism in the gene of the fibrinogen b-chain is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels: A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol 1997;17:3489–94.PubMedGoogle Scholar
- 26.Benhague I, Poirier O, Nicaud V al. b-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996;93:440–49.Google Scholar